Sign in Register

Correction: STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03.

By Korenfeld M, Hurcikova M, Tatsuoka K, Tomciková D, Cheetham J, Kacerik M, STAR Study Investigators · · 1 min read

Save

Correction: Ophthalmology and Therapy (2026) 15:1685–1703https://doi.org/10.1007/s40123-026-01341-0

In this article, in the PLAIN LANGUAGE SUMMARY section, a sentence was incorrect which previously appeared as“Children receiving atropine 0.01% had 0.13 diopters less myopia worsening at 2 years than those receiving vehicle, while those using atropine 0.03% had 0.12 diopters less worsening.”

But should have been“Children receiving atropine 0.01% had 0.13D/year less myopia worsening at two years than those receiving vehicle, while those using atropine 0.03% had 0.12 D/year less worsening.”

The original article has been corrected.

Related articles

PubMed

Efficacy of Combined Highly Aspherical Lenslet Target (HALT) Spectacles and Low-Dose Atropine in Children with Poor Response to Atropine Monotherapy over 24 Months.

Objectives: To evaluate the 24-month efficacy of combining highly aspherical lenslet target (HALT) spectacle lenses with low-dose atropine (LDA) in children with poor response to atropine monotherapy. Methods: This prospective interventional cohort study included myopic children aged 6–11 years who continued to progress despite LDA (0.01–0.025%). Fifty children completed 12 months of follow-up and 48 completed 24 months. At 12 months, atropine dosage was maintained, reduced, or increased accordi...

PubMed

Systematic review of atropine cost-effectiveness in childhood myopia management.

Background Childhood myopia is a global public health concern, with rising prevalence and a significant economic burden due to complications like retinal detachment and macular degeneration. Low-dose atropine (LDA) range 0.01%–0.05% is a clinically effective intervention for slowing myopia progression. However, its economic value remains under-evaluated across diverse settings. Methods and Findings We conducted a systematic review following PRISMA guidelines and registered in PROSPERO (CRD420...